Sensyne Health signs collaboration agreement with Bayer to accelerate the development of new treatments for cardiovascular disease using Clinical Artificial Intelligence

Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announces that it has signed an initial two-year collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease using Sensyne Health's proprietary clinical AI technology platform. The initial agreement will generate revenues for Sensyne Health of £5 million across the two-year collaboration. Sensyne Health's partner NHS trusts will receive a 4% share of all revenues generated by Sensyne Health under this collaboration. This will be in addition to the NHS Trust's existing shareholdings in Sensyne Health plc. The NHS Long Term Plan identifies cardiovascular disease as a clinical priority and the leading condition where lives can be saved by the NHS over the next 10 years.